Posted by psycHarvard on September 5, 2002, at 23:16:05
In reply to Re: Fewer s/e with Lexapro - where's the evidence?, posted by Bill L on September 3, 2002, at 9:48:28
I am a clinical instructor in Psychology with Harvard and I have had experience in depth with Lexapro since it was licenced by forest from Lundbeck in 98.... yes that is right it has been developed over a few years now and the reason that forest is now promoting Lexapro is simple and so many people here are uninformed and jumping to conclusions that I had to spell it out for them...
Lexapro is the next generation in SRI therapy.... next generation remember that it is important... first generation SSRI (Lexapro is in the SRI class) was Fluoxetine and there has been no huge improvement in SSRIs since then... a little cleaner and little more tolerable... so in that respect lost boy is correct... but now this is where some of you may feel challenged... Lexapro is the next generation of SRI therapy... what this means is basically that Lexapro is the most selective of any anti depressant... for 5HT without hitting on any of the other monos... this will decrease AE profile and reduce psycho activating events... I am trying to keep this as simple as possible... Lexapro has advantages over other anti depressant due to the fact that it only hits one mono as hundreds of studies show (Freemantle is a good one) that any more than one will just cause more AEs and a decrease in pat compliance... at any rate the SNRIs available only hit both 5HT and NE at the highest titrated dose so if you are on anything less you have fallen for a marketing ploy.... not that I do not believe that they are efficacious.
I have a lot of information that I am willing to share but I will only mention a bit at a time.
poster:psycHarvard
thread:109458
URL: http://www.dr-bob.org/babble/20020829/msgs/118969.html